Citable filing context

CVS filing events and research context

Server-rendered

CVS's research view summarizes recent SEC filing context, starting with management_change from May 18, 2026.

CVS filing events and research context
FiledItemContext
May 18, 2026management_changeCVS stockholders elected 13 nominees to the Board of Directors at the 2026 Annual Meeting.
Mar 19, 2026management_changeCVS Health elected John E. Gallina to its Board of Directors, effective March 19, 2026.
Feb 10, 2026earningsCVS Health reported Q4 2025 revenue of $105.7B and GAAP EPS of $2.30, with full-year revenue of $402.1B.
Feb 10, 2026Guidance: adjusted_eps7.00 to 7.20
Feb 10, 2026Guidance: cash_flow_from_operations9.00 to not reported
Feb 10, 2026Guidance: gaap_diluted_eps5.94 to 6.14
Feb 10, 2026businessCVS operates across Health Care Benefits (Aetna), Health Services (CVS Caremark, Signify Health, Oak Street Health), and Pharmacy & Consumer Wellness (CVS Pharmacy). The Health Care Benefits segment reported revenue growth in its Government business, aided by the Inflation Reduction Act, and an improved Medical Benefit Ratio of 91.2% in 2025. However, total medical membership decreased by 504,000, and the company is exiting individual Public Exchanges in 2026, with proposed 2027 Medicare Advantage rates showing a minimal 0.09% increase. The Health Services segment incurred a significant $5.7 billion goodwill impairment charge in 2025 for its Health Care Delivery unit (Oak Street Health), attributed to elevated utilization, revised growth projections, and clinic closures. This segment also recorded $291 million in PBM litigation and $288 million in Accountable Care asset losses. Pharmacy & Consumer Wellness revenue grew from drug mix and prescription volume, including Rite Aid acquisitions, despite reimbursement pressure. This segment faced $929 million in Omnicare litigation charges, leading to the deconsolidation of Omnicare Entities in September 2025. CVS generated $402.07 billion in revenues and $14.44 billion in adjusted operating income in 2025, with operating cash flow rising to $10.64 billion. The company holds $63.71 billion in long-term debt, and its long-term debt ratings carry a "Negative" outlook from Fitch and S&P. Store count decreased to 8,979, reflecting strategic closures.
Feb 10, 2026mdaCVS's financial performance is significantly influenced by payment timing, with Medicare Part D and employer group reconciliations causing working capital volatility, while most pharmacy revenues from third-party programs settle within 30 days. The company operates under extensive government regulation, particularly in Medicare and Medicaid. Key risks include changes to Medicare Advantage payment rates (e.g., 2026 saw a 7.16% increase, 2027 proposes 2.54%), evolving risk adjustment methodologies, and stringent Medical Loss Ratio (MLR) requirements, which could impact profitability and contract eligibility. The Inflation Reduction Act will reshape Part D liability and introduce drug price negotiations from 2026, affecting product design and premiums. Medicaid faces reduced eligibility and funding changes from the Working Families Tax Cut Act of 2025. Frequent audits (e.g., RADV), DOJ investigations, and anti-remuneration laws necessitate substantial compliance resources, carrying risks of significant fines or program exclusion. Uncertainty surrounding the 340B Drug Pricing Program's future also poses a financial risk.

Source: SEC EDGAR filing text and events; period May 18, 2026; filed May 18, 2026.

Continue research

Keep researching CVS

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →